Wave Life Sciences (WVE) Q4 2024 earnings summary

Executive summary

• Achieved significant clinical progress in 2024, including positive data in AATD, DMD, and HD programs, and advanced RNA editing into the clinic.

• Initiated clinical development and dosing in INLIGHT trial for WVE-007 in obesity, with clinical data expected in H2 2025.

• Maintained strong momentum into 2025 with key milestones expected across all clinical programs, including IND submission for WVE-003 Phase 2/3 in HD in H2 2025.

• Multi-dosing ongoing in RestorAATion-2 trial for WVE-006 in AATD; data expected in 2025.

• Cash and cash equivalents of $302.1M as of Dec 31, 2024, with runway into 2027.

Financial highlights

• Q4 2024 revenue was $83.7M, up from $29.1M in Q4 2023; full-year 2024 revenue was $108.3M, down from $113.3M in 2023.

• Q4 2024 net income was $29.3M, compared to a net loss of $16.3M in Q4 2023; full-year 2024 net loss was $97.0M, compared to $57.5M in 2023.

• Ended 2024 with $302.1M in cash and equivalents, up from $200.4M at end of 2023, driven by financing and milestone payments.

• R&D expenses rose to $159.7M in 2024 (from $130M), mainly due to obesity, AATD, and DMD programs.

• G&A expenses increased to $59M for the year (from $51.3M).

Outlook and guidance

• Cash runway projected to fund operations into 2027, excluding potential future GSK collaboration payments.

• Initial data from the WVE-007 obesity trial expected in H2 2025; DMD 48-week data and regulatory feedback anticipated by end of March 2025.

• Data from AATD multi-dose and higher-dose cohorts expected in 2025; additional RNA editing programs to enter clinic in 2026.

• Phase 2/3 HD study using caudate atrophy as a primary endpoint planned, with IND submission in H2 2025.